Devices & Diagnostics

Global market for neuromodulation devices to grow to $6.8 billion by 2017

A new market report from MarketsandMarkets, a Dallas-based market research firm, is projecting that the global market for neuromodulation devices is set to grow to $6.8 billion by 2017. Another report from October estimated that this same market will increase to $7.07 billion in 2018. Neuromodulation devices, whether implanted or external, treat certain diseases by […]

A new market report from MarketsandMarkets, a Dallas-based market research firm, is projecting that the global market for neuromodulation devices is set to grow to $6.8 billion by 2017.

Another report from October estimated that this same market will increase to $7.07 billion in 2018.

Neuromodulation devices, whether implanted or external, treat certain diseases by sending mild electrical pulses and/or drug infusion to a target nerve. The report notes that this is the fastest-growing segment of the broader medical devices sector driven by higher demand for less invasive and minimally invasive alternatives to the treatment of chronic pain, epilepsy, obesity, urinary incontinence and stroke and brain injury among other conditions.

An aging population together with the rise of age-related diseases like Alzheimer’s, epilepsy, Parkinson’s disease and spinal cord injury is fueling the market.

The market is divided into two broad segments: internal neurostimulation, which involves implanting the electrical pulse generator, and external neurostimulation, where the mild electrical pulses are provided from outside the body. The former market is subdivided into the following procedures: spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation and gastric electrical stimulation.

The external stimulation market is subdivided into transcranial magnetic stimulation and transcutaneous electrical nerve stimulation.

Some companies who are the dominant players in the neuromodulation field are Medtronic, St. Jude Medical, Cyberonics and Boston Scientific, while some emerging companies are Functional Neurmodulation, which aims to treat Alzheimer’s with deep brain stimulation; MicroTransponder, which is using neurostimulation to treat tinnitus and NeuroSigma, which is targeting a whole host of conditions including epilepsy, post-traumatic stress disorders and obesity.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

A company that has found success in treating incontinence using external neurostimulation is Uroplasty.